BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 10658448)

  • 1. [Global analysis of data from studies with PDE1 alpha-cyslodextrin].
    Laurora G; Belcaro G; Cesarone MR; Incandela L; De Sanctis MT; Dugall M
    Minerva Cardioangiol; 1998 Oct; 46(10 Suppl 1):65-8. PubMed ID: 10658448
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Analysis of costs and results of prostaglandin (PGE1 alpha-cyclodestrin) therapy of peripheral arterial diseases].
    Bucci M; Iacobitti P; Laurora G; Cesarone MR
    Minerva Cardioangiol; 1998 Oct; 46(10 Suppl 1):9-15. PubMed ID: 10658439
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ["Responders and non-responders" to PGE1 and alpha-cyclodextrin].
    De Sanctis MT; Incandela L; Iacobitti P
    Minerva Cardioangiol; 1998 Oct; 46(10 Suppl 1):31-6. PubMed ID: 10658442
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Reduction of cardiovascular morbidity/mortality in arteriopathies treated ith PGE1 alpha-cyclodextrin].
    Belcaro G; Bucci M; Cesarone MR; Incandela L; De Sanctis MT
    Minerva Cardioangiol; 1998 Oct; 46(10 Suppl 1):51-4. PubMed ID: 10658445
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [European trial of PGE1 alpha cyclodextrin. Short-term vs. long-term therapy in intermittent claudication].
    Laurora G; Corsi M; Bucci M; Cesarone MR; Belcaro G; Dugall M
    Minerva Cardioangiol; 1998 Oct; 46(10 Suppl 1):21-9. PubMed ID: 10658441
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Increasing transcutaneous PO2 in arteriopathies during treatment with PGE1 alpha-cyclodextrin].
    Belcaro G; Cesarone MR
    Minerva Cardioangiol; 1998 Oct; 46(10 Suppl 1):37-43. PubMed ID: 10658443
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Intramuscular injections of PGE1 in patients with severe claudication].
    Corsi M; Laurora G; Cesarone MR
    Minerva Cardioangiol; 1998 Oct; 46(10 Suppl 1):59-63. PubMed ID: 10658447
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Cardiovascular morbidity/mortality modified by the use of FGE1 alpha-cyclodextran and calcium heparin in patients with severe vascular diseases].
    Belcaro G; Cesarone MR; Bucci M; Iacobitti P; Dugall M
    Minerva Cardioangiol; 1998 Oct; 46(10 Suppl 1):55-8. PubMed ID: 10658446
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Circadian variations of cutaneous blood flow in normal subjects and in patients with peripheral arteriopathies. Effect of PGE1 and alpha-cyclodextrin].
    Laurora G; Belcaro G
    Minerva Cardioangiol; 1998 Oct; 46(10 Suppl 1):45-9. PubMed ID: 10658444
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Treatment of severe intermittent claudication: ORACLE-PGE1 short term study. A randomised 40-week study. Evaluation of efficacy and costs].
    Cesarone MR; Belcaro G; Nicolaides AN; Griffin M; Geroulakos G; Ramaswami G; Cazaubon M; Barsotti A; Vasdekis S; Christopoulos D; Agus G; Bavera P; Mondani P; Ippolito E; Flenda F
    Minerva Cardioangiol; 2002 Dec; 50(6):683-90. PubMed ID: 12473989
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Intra-arterial infusion of PGE1 alpha cyclodextrin].
    Laurora G; Cesarone MR; Belcaro G; Incandela L; De Sanctis MT; Fascetti E; D'Archivio C
    Minerva Cardioangiol; 1998 Oct; 46(10 Suppl 1):17-20. PubMed ID: 10658440
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nomograms used to define the short-term treatment with PGE(1) in patients with intermittent claudication and critical ischemia. The ORACL.E (Occlusion Revascularization in the Atherosclerotic Critical Limb) Study Group. The European Study.
    Belcaro G; Nicolaides AN; Cipollone G; Laurora G; Incandela L; Cazaubon M; Barsotti A; Ledda A; Errichi BM; Cornelli U; Dugall M; Corsi M; Mezzanotte L; Geroulakos G; Fisher C; Szendro G; Simeone E; Cesarone MR; Bucci M; Agus G; De Sanctis MT; Ricci A; Ippolito E; Vasdekis S; Christopoulos D; Helmis H
    Angiology; 2000 Aug; 51(8 Pt 2):S3-13; discussion S14. PubMed ID: 10959506
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-chlamydial antibiotic therapy for symptom improvement in peripheral artery disease: prospective evaluation of rifalazil effect on vascular symptoms of intermittent claudication and other endpoints in Chlamydia pneumoniae seropositive patients (PROVIDENCE-1).
    Jaff MR; Dale RA; Creager MA; Lipicky RJ; Constant J; Campbell LA; Hiatt WR
    Circulation; 2009 Jan; 119(3):452-8. PubMed ID: 19139383
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sirolimus for below the knee lesions: mid-term results of SiroBTK study.
    Commeau P; Barragan P; Roquebert PO
    Catheter Cardiovasc Interv; 2006 Nov; 68(5):793-8. PubMed ID: 17039538
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outpatient treatment of severe peripheral ischemia with intravenous intermittent low-dose iloprost. An open pilot study.
    Banyai S; Jenelten R; Wagner S; Allmann J; Banyai M; Koppensteiner R
    Int Angiol; 2002 Mar; 21(1):36-43. PubMed ID: 11941272
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Evaluation of cutaneous necrosis risk in peripheral arterial diseases].
    D'Eri A; Martini R; Cordova RM; Trevisan G; Andreozzi GM
    Minerva Cardioangiol; 2002 Jun; 50(3):239-44. PubMed ID: 12107403
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PGE(1) treatment of severe intermittent claudication (short-term versus long-term, associated with exercise)--efficacy and costs in a 20-week, randomized trial.
    Belcaro G; Nicolaides AN; Agus G; Cesarone MR; Geroulakos G; Pellegrini L; De Sanctis MT; Incandela L; Ricci A; Mondani P; De Angelis R; Ippolito E; Barsotti A; Vasdekis S; Ledda A; Christopoulos D; Errichi BM; Helmis H; Cornelli U; Ramaswami G; Dugall M; Bucci M; Martines G; Ferrari PG; Corsi M; Di Francescantonio D
    Angiology; 2000 Aug; 51(8 Pt 2):S15-26. PubMed ID: 10959507
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Midterm results of prostaglandin E1 treatment in patients with lumbar spinal canal stenosis accompanied by intermittent claudication.
    Nakanishi K; Tanaka M; Misawa H; Takigawa T; Ozaki T
    Spine (Phila Pa 1976); 2008 Jun; 33(13):1465-9. PubMed ID: 18520942
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of severe intermittent claudication with PGE1--a short-term vs a long-term infusion plan--a 20 week, European randomized trial--analysis of efficacy and costs.
    Belcaro G; Laurora G; Nicolaides AN; Agus G; Cesarone MR; DeSanctis MT; Incandela L; Ricci A; Cazaubon M; Ippolito E; Barsotti A; Vasdekis S; Ledda A; Iacobitti P; Christopoulos D; Errichi BM; Helmis H; Cornelli U; Ramaswami G; Bucci M; Ferrari PG; Corsi M; Pomante P; Mezzanotte L; Geroulakos G
    Angiology; 1998 Nov; 49(11):885-94; discussion 895. PubMed ID: 9822044
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Severe intermittent claudication: PGE1 treatment. A 40-week registry, efficacy and costs].
    Luzzi R; Belcaro G; Ippolito E; Dugall M; Cesarone MR; Scoccianti M; Errichi BM; Pellegrini L; Ciammaichella G; Ledda A; Ricci A; Cornelli U; Feragalli B; Hosoi M; Corsi M; Simeone E; Agus GB
    Minerva Cardioangiol; 2012 Aug; 60(4):405-13. PubMed ID: 22858918
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.